Shree Ganesh Biotech Q1 FY27 net loss 57.32 lakhs vs profit YoY

Pat NegativeEbitda Margin CompressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹0.55

prior close

₹0.54

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-1.3% vs market

Pharmaceuticals & Biotechnology peers, median of 170sector · industry level-0.0%+0.0% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+1.9

15m

+0.0

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+1.3-1.3-0.0+0.0

Next day

-1.8+1.6-3.5+0.2-2.0

+0.0+1.7-1.7+0.5-0.5

-3.6+1.6-5.3+1.0-4.7

-1.8+1.5-3.3+1.2-3.0

-5.5+1.8-7.3+1.0-6.5

-5.5+2.1-7.5+0.5-5.9

15d

-7.3+3.2-10.5-0.0-7.3

-5.5+3.7-9.2+1.7-7.2

-14.5+1.1-15.7+0.9-15.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals & Biotechnology peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 (June 2026) net loss was 57.32 lakhs versus a profit of 32.70 lakhs in the same quarter last year. Revenue from operations was nearly flat at 142.99 lakhs versus 138.36 lakhs. However, cost of materials consumed jumped to 186.67 lakhs from 111.97 lakhs, pushing total expenses to 232.32 lakhs and turning operations into a loss. Q4 FY26 also reported a loss of 14.93 lakhs. Full year FY26 had a profit of 37.76 lakhs. Auditor Bipin and Co gave an unmodified review.

Likely market impact

Rising costs have pushed the company into losses two quarters in a row, a red flag for shareholders.